Luxa Biotechnology Awarded $4 Million CIRM Grant to Support Clinical Trial of Adult RPESC-RPE-4W Therapy for Dry Age-related Macular Degeneration
Summary
We are impressed with the stem cell-based replacement approach developed by Luxa Biotechnology and delighted to support their groundbreaking efforts to restore vision and hope to patients with dry AMD.Dr. LuxaBio is a partnership between the NSCI research institute and Y2 Solution, a Korean company, to evaluate RPESC in a clinical trial to test the safety and efficacy of RPE progenitor stage progeny as a therapy for dry AMD. In 2022, NSCI partnered with Y2 Solution to create Luxa Biotechnology to advance the RPESC as therapy for dry age-related macular degeneration, in collaboration with the NIH National Eye Institute, Cedars-Sinai Biomanufacturing Center, Emmes Corporation, and the University of Michigan Kellogg Eye Center.At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of todays most promising stem cell technologies. With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is one of the worlds largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality.